» Articles » PMID: 18486811

Oral Bisphosphonate-induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment

Citing Articles

Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis.

Awad M, Sun C, Jernigan J, Elsalanty M J Am Dent Assoc. 2019; 150(8):664-675.e8.

PMID: 31256803 PMC: 6839407. DOI: 10.1016/j.adaj.2019.03.006.


Dental implant in a multiple myeloma patient undergoing bisphosphonate therapy: A case report.

Bayani M, Anooshirvani A, Keivan M, Mohammad-Rabei E Clin Case Rep. 2019; 7(5):1043-1048.

PMID: 31110742 PMC: 6509921. DOI: 10.1002/ccr3.2150.


Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy.

Koth V, Figueiredo M, Salum F, Cherubini K Dentomaxillofac Radiol. 2017; 46(4):20160260.

PMID: 28107028 PMC: 5595000. DOI: 10.1259/dmfr.20160260.


Evaluation of the predisposing factors and involved outcome of surgical treatment in bisphosphonate-related osteonecrosis of the jaw cases including bone biopsies.

Kim T, Seo W, Koo C, Lee J J Korean Assoc Oral Maxillofac Surg. 2016; 42(4):193-204.

PMID: 27595086 PMC: 5009193. DOI: 10.5125/jkaoms.2016.42.4.193.


Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy.

Thumbigere-Math V, Michalowicz B, Hughes P, Basi D, Tsai M, Swenson K J Oral Maxillofac Surg. 2015; 74(4):738-46.

PMID: 26501428 PMC: 4909718. DOI: 10.1016/j.joms.2015.09.028.